KLEINBERG DL

Last name: KLEINBERG DL

2011 (v1)

Publication

Metadata-only

Pasireotide, an IGF-I action inhibitor, prevents growth hormone and estradiol-induced mammary hyperplasia.

Kleinberg DL AMERI, PIETRO Singh B.

Mammary hyperplasia increases breast cancer risk. Tamoxifen prevents breast cancer in women with atypical hyperplasia, but has serious side effects. As estradiol action requires IGF-I, direct inhibition of IGF-I action theoretically might be an efficacious alternative to tamoxifen. After hypophysectomy and oophorectomy, 21-day-old female rats...

Uploaded on: April 14, 2023
2012 (v1)

Publication

Metadata-only

Alternative approach to insulin-like growth factor-1 inhibition for treatment of breast cancer.

AMERI, PIETRO Danoff A Kleinberg DL

No description

Uploaded on: April 14, 2023
2011 (v1)

Publication

Metadata-only

IGF1 promotes survival of mast cells and regulates their number in the developing mammary gland

AMERI, PIETRO MURIALDO, GIOVANNI FERONE, DIEGO

No description

Uploaded on: March 31, 2023
2012 (v1)

Publication

Metadata-only

IGF-I inhibition by pasireotide reverses the mammary phenotype of a novel mouse model of Brca1 deficiency.

AMERI, PIETRO Fernandez Garcia I Martinez Ruiz H

No description

Uploaded on: April 14, 2023
2014 (v1)

Publication

Metadata-only

Insulin-like growth factor-I inhibition with pasireotide decreases cell proliferation and increases apoptosis in pre-malignant lesions of the breast: a phase 1 proof of principle trial.

Singh B Smith JA Axelrod DM

IntroductionEstrogen inhibition is effective in preventing breast cancer in only up to 50% of women with precancerous lesions and many experience side effects that are poorly tolerated. As insulin-like growth factor I (IGF-I) underlies both estrogen and progesterone actions and has other direct effects on mammary development and carcinogenesis,...

Uploaded on: April 14, 2023

KLEINBERG DL

Recent uploads